Abcam (ABCM) Financial Analysis & Valuation | Quarter Chart
Abcam (ABCM)
ABCMPrice: $23.99
Fair Value: 🔒
🔒score
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex i... more
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and... more
Description
Shares
| Market Cap | $5.52B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | GB | CEO | Alan Thomas Hirzel BS, |
| IPO Date | 2020-10-22 | CAGR | 0.28% |
| Employees | 1,760 | Website | www.abcam.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
ABCM chart loading...
Fundamentals
Technicals
| Enterprise Value | $4.62B | P/E Ratio | 2399 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 3.88 |
| P/CF Ratio | 40.46 | P/FCF Ratio | — |
| EPS | $0.01 | EPS Growth 1Y | -66.6% |
| EPS Growth 3Y | -83.27% | EPS Growth 5Y | -79.31% |
| Revenue Growth 1Y | -7.03% | Gross Margin | 0.71% |
| Operating Margin | 0.02% | Profit Margin | 0.01% |
| ROE | 0.01% | ROA | — |
| ROCE | 0.01% | Current Ratio | 1.13 |
| Quick Ratio | 0.82 | Cash Ratio | 0.51 |
| Debt/Equity | 0.35 | Interest Coverage | 3.76 |
| Altman Z Score | 9.45 | Piotroski Score | 6 |